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In the continued search for inhibitors of enoyl-acyl carrier
protein (ACP) reductase, we found that four acyl-
benzenediol sulfate metabolites from Streptomyces sp.
AN1761 potently inhibited bacterial enoyl-ACP reductases
of Staphylococcus aureus, Streptococcus pneumoniae, and
Mycobacterium tuberculosis. Their structures were identified
as panosialins A, B, wA, and wB by MS and NMR data.
They showed stronger inhibition against S. aureus FabI
and S. pneumoniae FabK with IC50 of 3-5 µM than M.
tuberculosis InhA with IC50 of 9-12 µM. They also
exhibited a stronger antibacterial spectrum on S. aureus
and S. pneumoniae than M. tuberculosis. In addition, the
higher inhibitory activity of panosialin wB than panosialin
B on fatty acid biosynthesis was consistent with that on
bacterial growth, suggesting that they could exert their
antibacterial activity by inhibiting fatty acid synthesis.
Key words: Panosialin, enoyl-ACP reductase, inhibitor,
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Bacterial fatty acid synthesis (FAS II) is an attractive
antibacterial target since FAS is organized differently in
bacteria and mammals [2, 4]. Bacterial enoyl-ACP reductase
catalyzes the final and rate-limiting step in bacterial fatty
acid synthesis [8, 11]. There are three isoforms, FabI,
FabK, and FabL, in enoyl-ACP reductase. FabI is distributed
broadly throughout the majority of bacteria including S.
aureus, whereas Streptococcus pneumoniae contains only
FabK, Enterococcus faecalis and Pseudomonas aeruginosa
contain both FabI and FabK, and Bacillus subtilis contains
both FabI and FabL. InhA is a FabI homolog in M.
tuberculosis. Bacterial enoyl-ACP reductase has been
validated as an excellent target for antibacterial drug
development since FabI and InhA have been identified as
the antibacterial target of triclosan and isoniazid, respectively
[7, 9]. Triclosan is a broad-spectrum biocide used in a wide
range of consumer goods, and isoniazid has been utilized
for 50 years in the treatment of tuberculosis. Therefore,
inhibitors of enoyl-ACP reductase could be interesting lead
compounds for treatment of multidrug-resistant bacteria.
In our continued screening of inhibitors of enoyl-ACP
reductase from microbial resources [6, 12], four acyl-
benzenediol sulfate metabolites were isolated from
Streptomyces sp. AN1761. The isolated compounds were
identified as panosialins A (1), B (2), wA (3), and wB (4),
rare microbial metabolites, by spectral analysis (Fig. 1) [5].
Panosialins A and B have been reported as the inhibitors of
viral sialidase [1] and panosialins A, B, wA, and wB as
inhibitors of glycosidases together with brief antibacterial
activity [10]. Their antibacterial activity, however, has yet
to be thoroughly examined. In this study, we report the
isolation, inhibitory activity against bacterial enoyl-ACP
reductases and intracellular fatty acid biosynthesis, and
antibacterial activity of 1-4.
The strain AN1761 was isolated from a soil sample
collected from a mountain located near Gongju-city,
Chungcheongnam-do, Korea. This strain was identified as
a Streptomyces species on the basis of its 16S rDNA
sequence. Fermentation was conducted in a liquid culture
medium containing soluble starch 1%, glucose 2%,
soybean meal 2.5%, beef extract 0.1%, yeast extract 0.4%,
NaCl 0.2%, K2HPO4 0.025%, and CaCO3 0.2% (adjusted
to pH 7.2 before sterilization). A piece of the AN1761
strain from a mature plate culture was inoculated into a
500 ml Erlenmeyer flask containing 80 ml of the above
sterile seed liquid medium and cultured for 3 days on a
rotary shaker (150 rpm) at 28oC. For the production of
active compounds, 5 ml of the seed culture was transferred
into 500 ml Erlenmeyer flasks (65 flasks) containing 100 ml
of the same medium, and then cultivated for 7 days at
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28oC. The fermented whole medium (2 L) was extracted
with 50% acetone and the extract was concentrated in
vacuo to an aqueous solution, which was then extracted
three times with an equal volume of EtOAc. The EtOAc
extract was concentrated to dryness in vacuo. The crude
extract was then subjected to SiO
2
 column
chromatography followed by stepwise elution with CHCl3-
MeOH (10:1, 5:1, 3:1, 1:1) to afford two active fractions.
The first active fractions eluted with CHCl3-MeOH (5:1)
were pooled and concentrated in vacuo. The residue
dissolved in MeOH was purified via preparative SiO
2
 thin-
layer chromatography developed with CHCl3-MeOH (3:1)
containing 0.1% TFA to yield an active band (12.7 mg) at
an Rf of 0.35. The active band was further purified by
reversed-phase HPLC. The column was eluted with ACN-
25 mM sodium phosphate (pH 7.0) (65:35) at a flow rate
of 7 ml/min to afford 3 and 4, with retention times of 14.8
and 16.2 min, respectively. They were desalted by a MCI
gel column to yield 2.6 mg of 3 and 4.7 mg of 4. The
second active fractions eluted with CHCl3-MeOH (3:1)
were pooled and concentrated in vacuo. The residue
dissolved in MeOH was again applied to a Sephadex LH-
20 column and then eluted with MeOH. The active
fractions residue dissolved in MeOH was purified via
preparative SiO
2
 thin-layer chromatography developed
with CHCl3-MeOH (2:1) containing 0.1% TFA to yield an
active band (16.5 mg) at an Rf of 0.2. The active band was
further purified by reversed-phase HPLC chromatography
eluted with ACN-50 mM sodium phosphate (pH 7.0)
(78:22) at a flow rate of 3.5 ml/min to afford 1 and 2, with
retention times of 34.8 and 38.5 min, respectively. They
were also desalted by a MCI gel column to yield 2.5 mg of
1 and 5.1 mg of 2. The structures of 1-4 were determined
as panosialins A, B, wA, and wB, respectively, by NMR
and MS spectral data [5, 10]. The 1H- and 13C-NMR data
of panosialins A and B were reported for the first time in
this study. NMR spectra were recorded on a Bruker
Biospin Avance 500 spectrometer (Korea Basic Science
Institute). ESI-MS data were obtained with a Finnigan
Navigator spectrometer.
Compound 1: C21H34Na2O8S2, a white powder. 
1H-NMR
(500 MHz, CD3OD) : δ 7.05 (1H, dd, J = 2.0, 2.0, H-2),
6.99 (2H, d, J = 2.0, H-4 and 6), 2.58 (2H, t, J = 7.5, H2-1'),
1.61 (2H, m, H2-2'), 1.51 (1H, q, J = 7.0, H2-13'), 1.28
(18H, m, H2-3' to 11'), 1.17 (2H, m, H2-12'), 0.87 (6H, d, J
= 7.0, H3-14' and 15'); 
13C-NMR (200 MHz, CD3OD) : δ
154.3 (C-1 and 3), 145.9 (C-5), 118.9 (C-4 and 6), 113.4
(C-2), 40.4 (C-12'), 37.0 (C-1'), 32.5 (C-2'), 30.6 – 31.2 (C-
3' to 10'), 29.3 (C-13'), 28.7 (C-11'), 23.2 (C-14' and 15');
ESI-MS: 547.3 [M+Na]+, 501.3 [M-Na]-.
Compound 2: C21H34Na2O8S2, a white powder. 
1H-NMR
(500 MHz, CD3OD) δ 7.05 (1H, dd, J = 2.0, 2.0, H-2), 6.99
(2H, d, J = 2.0, H-4 and 6), 2.58 (2H, t, J = 7.5, H2-1'), 1.61
(2H, m, H2-2'), 1.28 (24H, m, H2-3' to 14'), 0.89 (3H, d, J =
7.5, H3-15'); 
13C-NMR (200 MHz, CD3OD) δ: 154.3 (C-1
and 3), 145.9 (C-5), 118.9 (C-4 and 6), 113.4 (C-2), 37.0
(C-1'), 33.2 (C-13'), 32.5 (C-2'), 30.6 - 30.9 (C-3' to 12'),
23.9 (C-14'), 14.6 (C-15'); ESI-MS: 547.3 [M+Na]+, 501.3
[M-Na]-.
Compound 3: C21H35NaO5S, a white powder. 
1H-NMR
(500 MHz, CD3OD) : δ 6.62 (1H, dd, J = 2.1, 2.0, H-4),
6.60 (1H, dd, J = 2.1, 2.0, H-2), 6.42 (1H, dd, J = 2.1, 2.0,
H-6), 2.50 (2H, t, J = 7.5, H2-1'), 1.58 (2H, m, H2-2'), 1.52
(1H, q, J = 7.0, H2-13'), 1.28 (18H, m, H2-3' to 11'), 1.16
(2H, m, H2-12'), 0.87 (6H, d, J = 7.0, H3-14' and 15'); 
13C-
NMR (200 MHz, CD3OD) : δ 159.1 (C-1), 154.8 (C-3),
146.2 (C-5), 113.8 (C-4), 113.1 (C-6), 107.2 (C-2), 40.4
(C-12'), 37.1 (C-1'), 32.5 (C-2'), 30.5 - 31.2 (C-3' to 10'),
29.3 (C-13'), 28.7 (C-11'), 23.2 (C-14' and 15'); ESI-MS :
445.4 [M+Na]+, 399.4 [M-Na]-.
Compound 4: C21H35NaO5S, a white powder. 
1H-NMR
(500 MHz, CD3OD) : δ 6.61 (1H, dd, J = 2.1, 2.0, H-4),
6.59 (1H, dd, J = 2.1, 2.0, H-2), 6.42 (1H, dd, J = 2.1, 2.0,
H-6), 2.50 (2H, t, J = 7.5, H2-1'), 1.58 (2H, m, H2-2'), 1.28
(24H, m, H2-3' to 14'), 0.88 (3H, d, J = 7.5, H3-15'); 
13C-
NMR (200 MHz, CD3OD) : δ 159.0 (C-1), 154.8 (C-3),
146.1 (C-5), 113.8 (C-4), 113.1 (C-6), 107.1 (C-2), 37.0
(C-1'), 33.2 (C-13'), 32.5 (C-2'), 30.5 - 30.9 (C-3' to 12'),
23.9 (C-14'), 14.6 (C-15'); ESI-MS: 445.4 [M+Na]+, 399.4
[M-Na]-.
Urushil was purchased from Alfa Aesar (Ward Hill,
MA, USA). Triclosan was purchased from Sigma. [1-14C]
Acetate (57 µCi/mol) and L-[U-14C] leucine (306 µCi/mol)
were purchased from Amersham.
S. aureus FabI, S. pneumoniae FabK, and M. tuberculosis
InhA enzymes were cloned, overexpressed, and purified as
Fig. 1. Structures of panosialins A (1), B (2), wA (3), and wB (4), and related compound.
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previously described [6, 13]. Assays were conducted in
half-area, 96-well microtiter plates. The compounds were
evaluated in 100 µl assay mixtures containing components
specific to each enzyme (see below). The reduction of the
trans-2-octenoyl N-acetylcysteamine (t-o-NAC thioester)
substrate analog was spectrophotometrically measured by
following the utilization of NADH or NADPH at 340 nm
at 30oC over the linear period of the assay. S. aureus FabI
assays contained 50 mM sodium acetate, pH 6.5, 400 µM
t-o-NAC thioester, 200 µM NADPH, and 150 nM S.
aureus FabI. The rate of decrease in the amount of
NADPH in each reaction well was measured using a
microtiter ELISA reader using SOFTmax PRO software
(Molecular Devices, CA, USA). The inhibitory activity
was calculated via the following formula: % of inhibition =
100 × [1−(rate in the presence of compound/ rate in the
untreated control)]. The IC50 values were calculated by
fitting the data to a sigmoid equation. An equal volume of
dimethyl sulfoxide solvent was used for the untreated
controls. FabK assays contained 100 mM sodium acetate,
pH 6.5, 2% glycerol, 200 mM NH4Cl, 50 µM t-o-NAC
thioester, 200 µM NADH, and 150 nM S. pneumoniae
FabK. InhA assays contained 30 mM PIPES buffer, pH 8.0,
100 µM t-o-NAC thioester, 100 µM NADPH, and 500 nM
M. tuberculosis InhA. 
Whole-cell antimicrobial activity on S. aureus, methicillin-
resistant S. aureus (MRSA), Streptococcus pneumoniae,
and Pseudomonas aeruginosa was determined via broth
microdilution, as previously described [13]. The test
strains were grown to mid-log phase in Mueller-Hinton
broth and diluted 1,000-fold in the same medium. Cells
(105/mL) were inoculated into Mueller–Hinton broth,
except that S. pneumoniae was inoculated into tryptic soy
broth containing 5% sheep blood, and then dispensed at
0.2 ml/well in 96-well microtiter plates. MICs were
determined in triplicate via the serial dilution of test
compounds. The MIC was defined as the concentration of
a test compound required to completely inhibit cell growth
at 30oC. Bacterial growth was determined by measuring the
absorption at 650 nm with a microtiter ELISA reader. The
minimal inhibitory concentration against Mycobacterium
tuberculosis (Mtb) H37Rv was determined by the green
fluorescent protein (GFP) reporter microplate assay [3].
Mtb H37Rv-GFP was grown in 10 ml of Middlebrook 7H9
broth (Difco, Sparks, MD, USA) supplemented with 50 mg/l
kanamycin, 0.2% (v/v) glycerol (Sigma Chemical Co.,
Saint Louis, MO, USA), 1.0 g of Casitone (Difco) per liter,
10% (v/v) OADC (oleic acid, albumin, dextrose, catalase;
Difco), and 0.05% (v/v) Tween 80 (Sigma) until its optical
density at 600 nm reached 0.4. Test compound solution
was added to 7H9 media, and 2-fold serial dilutions were
made in 7H9 broth in the microplates. The culture was
diluted 1:50 in 7H9, and was inoculated to yield 2 ×
105 CFU/ml in plate wells. The plates containing compounds
dilutions and Mtb were incubated at 37oC for 7 days, and
then fluorescence was measured in a Fluostar Optima
microplate fluorometer (BMG Labtech, Ortenberg, Germany)
in the bottom-reading mode with excitation at 485 nm and
emission at 520 nm. The MRC was defined as the lowest
concentration of extracts that inhibited fluorescence by
50% comparing with the fluorescence of bacteria-only
wells.
The effect of FabI inhibitors on the incorporation of
[1-14C]acetate and L-[U-14C]leucine in S. aureus was
measured as described previously [13]. S. aureus was
grown to the mid-log phase in LB medium. Each 1 ml
culture was treated with drugs for 10 min. An equal
volume of DMSO solvent was added to the untreated
control. For [1-14C]acetate incorporation, 2 µCi of [1-14C]
acetate was then added to the cultures and incubated at
37oC for 1 h in a shaker. After being harvested by
centrifugation, the cell pellets were washed twice with
PBS. The total cellular lipids were then extracted with
chloroform-methanol-water. The incorporated radioactivity
in the chloroform phase was measured by scintillation
counting. For L-[U-14C]leucine incorporation, 0.6 µCi of
L-[U-14C]leucine was added to the cultures and incubated
at 37oC for 1 h in a shaker. The incorporation was
terminated by the addition of 10% (w/v) TCA and cooling
on ice for 20 min. The precipitated material was collected
Table 1. Comparison of the inhibitory activity of compounds 1-5 against enoyl-ACP reductases, bacterial viability, and intracelluar
fatty acid biosynthesis in S. aureus.
Compounds
IC50 (µM) MIC (µg/ml) IC50 (µM)
saFabIa spFabKb mtInhAc S.a.d MRSAe S.p.f P.a.g M.t.h [14C]-acetate
1 4.3 3.9 11.8 128 128 256 256 256 n.t.i
2 5.4 5.2 8.5 128 128 256 256 256 55.3
3 3.0 5.2 9.6 16 16 64 64 128 n.t.
4 4.6 5.5 9.1 16 16 64 64 128 26.3
5 >100 >100 >100 >256 >256 >256 >256 >256 >500
Triclosan 0.66 >100 >100 0.01 0.01 >32 >64 16 0.04
a
S. aureus FabI; 
b
S. pneumoniae FabK; 
c
M. tuberculosis InhA; 
d
S. aureus RN4220; 
e
MRSA CCARM 3167; 
f
S. pneumoniae KCTC 5412; 
g, h
MRC, the lowest
concentration that prevented more than 50% of the bacterial growth, against P. aeruginosa KCTC 2004 and M. tuberculosis H37Rv, respectively; 
i
not tested.
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on Whatman GF/C glass microfiber filters, washed with
TCA and ethanol, dried, and counted in a scintillation
counter. Total counts incorporated at 1 h of incubation
without inhibitors ranged from >6,000 for [14C]leucine to
>10,000 for [14C]acetate.
Compounds 1-4 strongly inhibited S. aureus FabI in a
dose-dependent fashion with IC50 of 3-5 µM (Table 1).
They also showed the inhibitory activity on S. pneumoniae
FabK with a similar potency, but exhibited two-times
weaker inhibition on M. tuberculosis InhA. In order to
determine whether 1-4 inhibit the bacterial cell growth,
their antibacterial activity against S. aureus, methicillin-
resistant S. aureus (MRSA), S. pneumoniae, P. aeruginosa,
and M. tuberculosis were evaluated. Interestingly, 3 and 4
exhibited higher antibacterial activity against S. aureus
RN4220 and MRSA CCARM 3167 with a MIC of 16 µg/
ml than 1 and 2 with a MIC of 128 µg/ml (Table 1).
Similarly, 3 and 4 exhibited higher antibacterial activity
against S. pneumoniae and M. tuberculosis than 1 and 2.
In order to determine whether the antibacterial effects of
panosialins are attributable to the inhibition of intracellular
fatty acid biosynthesis, we attempted to ascertain whether
the compounds blocked the incorporation of acetate into
membrane fatty acids in vivo. We measured the effect of
the compounds on the incorporation of [1-14C] acetate into
the membrane fatty acids in S. aureus. Indeed, 4 inhibited
fatty acid synthesis in vivo as compared with the untreated
cells (Fig. 2). In addition, 4 showed stronger activity with
an IC50 of 26.3 µM than 2 with an IC50 of 55.3 µM (Table 1).
The higher inhibitory activity of 4 against the intracellular
fatty acid biosynthesis than 2 is consistent with its higher
antibacterial activity, suggesting that the antibacterial
activity of panosialins could be due to the inhibition of
fatty acid synthesis. Triclosan, used as a positive control,
inhibited acetate incorporation. In contrast, the incorporation
of leucine into proteins was not influenced by 4 at 30 µM.
Even though 4 started to inhibit protein biosynthesis at
100 µM, the compound clearly evidenced selective inhibition
for fatty acid synthesis. On the other hand, urushil (5), the
desulfated derivative of 4, did not show any inhibition
against enoyl-ACP reductases, fatty acid synthesis, and
bacterial growth. It suggested that the sulfate moiety in the
panosialins could be involved in the activity. In the
Lineweaver-Burk plot analysis (Fig. 3), 4 evidenced a
Fig. 2. Effects of panosialin wB (4) on fatty acid biosynthesis
and protein biosynthesis in S. aureus. 
The values were represented as the mean ± SD in duplicates obtained from
two independent experiments.
Fig. 3. The mechanism of inhibition of S. aureus FabI by panosialin wB (4) respective to t-o-NAC thioester (A) and Ki determination of
panosialin wB (B). 
(A) The reciprocals of the initial reaction and substrate concentrations are plotted. (B) The slope values of the lines from graph A are plotted versus the
inhibitor concentrations affording a line obtained by linear regression. The intercept point of this line with the x-axis gives an approximate Ki value of
0.49 µM for panosialin wB. The values were represented as the mean ± SD in triplicates obtained from two independent experiments. 
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mixed-type inhibition against S. aureus FabI with respect
to the substrate, t-o-NAC-thioester, with a Ki value of
0.49 µM. Interestingly, 3 and 4 showed the similar inhibitory
activity on the enoyl-ACP reductases, but had higher
inhibition on fatty acid synthesis as well as bacterial
growth than 1 and 2, which might be attributed to the
higher membrane permeability of 3 and 4, monosulfated,
than 1 and 2, disulfated.
Panosialins A-C have been reported as the inhibitors of
viral sialidase, acid phosphatase, and polygalacturonase
[1]. Yamada et al. [10] have re-isolated panosialins A-D
and wA-wD as inhibitors of glycosidases including α-
mannosidase, α-glucosidase, and β-glucosidase, from
Streptomyces sp. OH-5186. Panosialins wA-wD were
reported to show mitogenic activity in spleen cells.
Inhibitory activity of panosialins on FabI and fatty acid
synthesis was reported for the first time in this study. Since
an inhibitor targeting multiple enoyl-ACP reductases is
expected to exhibit a broader spectrum of activity,
panosialins that inhibit both FabI and FabK, and especially
InhA, may have potential for the development of a new
broad-spectrum antibacterial.
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